scholarly journals Solid Lipid Nanoparticles as Efficient Drug and Gene Delivery Systems: Recent Breakthroughs

2015 ◽  
Vol 5 (2) ◽  
pp. 151-159 ◽  
Author(s):  
Jafar Ezzati Nazhad Dolatabadi ◽  
Hadi Valizadeh ◽  
Hamed Hamishehkar
Author(s):  
Mahsa Mazdaei ◽  
Kofi Asare-Addo

The application of nanotechnology indrug delivery systems (DDS) has been researched widely and seen an advancementover the past three decades. Since the 1970s, nanoparticles were primarilyutilised in vaccine deliveries and cancer chemotherapy. In more recent years,they have been found to hold promises for broader applications such as inproteins and therapeutic gene delivery systems. To date, there have been only ahandful of nanocarrier-loaded drugs commercialised into the pharmaceuticalmarket. More research is thus needed to facilitate a breakthrough of theseproducts into the current market. This mini-review mainly focuses on four typesof commonly utilised organic nanocarriers including micelles, compactpolymerics, solid-lipid nanoparticles and liposomal vesicles and discusses theprogress and some challenges associated with these nanoparticles (NP). 


2016 ◽  
Vol 12 (5) ◽  
pp. 598-604 ◽  
Author(s):  
Tatiana N. Pashirova ◽  
Tatiana Andreani ◽  
Ana S. Macedo ◽  
Eliana B. Souto ◽  
Lucia Ya. Zakharova

Pharmaceutics ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 860
Author(s):  
Raneem Jnaidi ◽  
António José Almeida ◽  
Lídia M. Gonçalves

Glioblastoma multiforme (GBM) is the most common and malignant type of brain tumor. In fact, tumor recurrence usually appears a few months after surgical resection and chemotherapy, mainly due to many factors that make GBM treatment a real challenge, such as tumor location, heterogeneity, presence of the blood-brain barrier (BBB), and others. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) represent the most promising carriers for therapeutics delivery into the central nervous system (CNS) owing to their inherent ability to cross the BBB. In this review, we present the main challenges in GBM treatment, a description of SLNs and NLCs and their valuable role as drug carriers in GBM treatment, and finally, a detailed description of all modification strategies that aim to change composition of SLNs and NLCs to enhance treatment outcomes. This includes modification of SLNs and NLCs to improve crossing the BBB, reduced GBM cell resistance, target GBM cells selectively minimizing side effects, and modification strategies to enhance SLNs and NLCs nose-to-brain delivery. Finally, future perspectives on their use are also be discussed, to provide insight about all strategies with SLNs and NLCs formulation that could result in drug delivery systems for GBM treatment with highly effective theraputic and minimum undesirable effects.


Planta Medica ◽  
2020 ◽  
Vol 86 (05) ◽  
pp. 364-372 ◽  
Author(s):  
Jidapa Musika ◽  
Nuannoi Chudapongse

AbstractLupinifolin, a plant flavonoid, has been reported to possess various pharmacological effects. It most likely exerts low oral bioavailability because of poor water solubility. The objective of this study was to develop lipid nanocarriers as drug delivery systems to increase the gastrointestinal absorption of lupinifolin extracted from Albizia myriophylla. Three types of nanocarriers, lupinifolin-loaded solid lipid nanoparticles, lupinifolin-loaded nanostructured lipid carriers, and lupinifolin-loaded nanoemulsions, were prepared by an emulsification-sonication technique. All three types of nanocarriers loaded with lupinifolin, lupinifolin-loaded solid lipid nanoparticles, lupinifolin-loaded nanostructured lipid carriers, and lupinifolin-loaded nanoemulsions, were successfully synthesized. The lipid components chosen to formulate nanocarriers were tripalmitin and/or medium chain triglyceride. Physicochemical characterizations along with releasing profiles of lupinifolin-loaded lipid nanocarriers were compared. It was found that the best lipid nanocarrier for lupinifolin was lupinifolin-loaded nanostructured lipid carriers, which demonstrated the particle size of 151.5 ± 0.1 nm, monodispersity distribution with a polydispersity index of 0.24, negative surface charge at − 41.2 ± 0.7 mV, high encapsulation (99.3%), and high loading capacity (5.0%). The obtained lupinifolin-loaded nanostructured lipid carriers exhibited prolonged release in a simulated circulatory system but produced a low release in gastrointestinal conditions (3.7%). Intestinal permeability of the nanocarriers was further evaluated in everted intestinal sacs. The results from the ex vivo study indicated that lupinifolin-loaded nanostructured lipid carriers significantly increased the absorption of lupinifolin compared to the native form. In conclusion, lupinifolin-loaded lipid nanocarriers were successfully formulated as delivery systems to enhance its oral bioavailability. Further in vivo experiments are needed to validate the results from this study.


2013 ◽  
Vol 102 ◽  
pp. 391-397 ◽  
Author(s):  
Xia Huang ◽  
Yan-Jie Chen ◽  
Dai-Yin Peng ◽  
Qing-Lin Li ◽  
Xiao-Shan Wang ◽  
...  

2016 ◽  
Vol 10 (1) ◽  
pp. 85-95
Author(s):  
Tesfaye Gabriel

Background: Acne vulgaris (commonly called acne) is the most prevalent skin complication of different causes with a higher prevalence in adolescents. Topical administration is used as first-choice therapy in mild acne, whereas for moderate and severe acne, systemic administration is required in addition to topical therapy. Mechanisms by which treatments act are: normalizing shedding into the pore to prevent obstruction, destruction of P.acnes, suppression of inflammation, and hormonal management. Objective: This review focuses on the novel drug delivery systems displaying a strong ground for topical treatment of acne in order to enhance the therapeutic performance of the topical antiacne agents with improved patience compliance and a concomitant reduction in the side effects. Method: This literature review was obtained from electronic search on Pubmed, Google Scholars, Researchgate, Scimago, CABI, DOAJ, CiteFactor, GLOBAL HEALTH, Universal Impact Factor, Hinari among many others and also search was conducted on individual journals and manuals. Conclusion: Amongst various novel drug delivery systems, vesicular carriers like liposomes and niosomes, micro sponges, microemulsions, solid lipid nanoparticles, hydrogels, emulsifier-free formulations, fullerenes and aerosol foams have been reported as novel topical administration of antiacne drugs. Liposomes have been extensively explored and their ability to optimize and improve topical therapy has been proved by several clinical trials. Microemulsions, microsponges, solid lipid nanoparticles and hydrogels also exhibit a tremendous potential for commercialization.


Author(s):  
Chun Chan ◽  
Shi Du ◽  
Yizhou Dong ◽  
Xiaolin Cheng

: Lipid nanoparticles (LNPs) have been widely applied for drug and gene delivery. More than twenty years ago, Doxil TM was the first LNPs-based drug approved by the US Food and Drug Administration (FDA). Since then, with decades of research and development, more and more LNP-based therapeutics have been used to treat diverse diseases, which often offer the benefits of reduced toxicity and/or enhanced efficacy compared to the active ingredients alone. Here, we provide a review on recent advances in the development of efficient and robust LNPs for drug/gene delivery. We emphasize the importance of rationally combining experimental and computational approaches, especially those providing multiscale structural and functional information of LNPs, to the design of novel and powerful LNP-based delivery systems.


Sign in / Sign up

Export Citation Format

Share Document